Sponsored Links 
Amylin's Bad Byetta News
Print
ShareIn a note received just now from Zacks senior biotechnology analyst Jason Napodano, CFA, the Food & Drug Administration [FDA] just issued a warning on Amylin's (AMLN) diabetes drug, Byetta, on a potential risk for pancreatitis.
According to the report, there have been six reported cases, with two deaths in a recent-enough time frame that the FDA believes warnings doctors and patients is necessary. The stock is already down 10% on the news.
From the analyst: "We have a SELL on Amylin and continue to recommend investors avoid the name."
Read the full analyst report on AMLN
Read the full analyst report on AMLN
Loading Stories...
0.00 %
5.75